Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

22.74 +0.06 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,824,215
Open 22.47
Bid (Size) 22.00 (100)
Ask (Size) 23.20 (500)
Prev. Close 22.68
Today's Range 21.95 - 23.19
52wk Range 21.02 - 42.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill

Performance

YTD
-35.4%
-35.4%
1 Month
-16.8%
-16.8%
3 Month
-28.3%
-28.3%
6 Month
-27.2%
-27.2%
1 Year
-15.0%
-15.0%

More News

Read More
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom ↗
Via Chartmill
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears ↗
Via MarketBeat
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Via The Motley Fool
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends ↗
Via MarketBeat
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
Via The Motley Fool
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 22.74
When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 09/24/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.